GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy
February 27, 2024 07:45 ET
|
The Greater Cannabis Company, Inc.
BALTIMORE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation...
GCANRx Signs Licensing Agreement with Shaare Zedek Scientific for Innovative Neuropsychiatric Cannabinoid Therapy
August 19, 2021 09:45 ET
|
The Greater Cannabis Company, Inc.
BALTIMORE, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTCQB: GCAN) a cannabis innovator specializing in the development of pharmaceutical and...
Pivot Files Three New Provisional Patents for the Delivery of Cannabinoids
February 01, 2018 04:00 ET
|
Pivot Pharmaceuticals Inc.
VANCOUVER, British Columbia, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Pivot Pharmaceuticals Inc. (CSE:PVOT) (OTCQB:PVOTF) (“Pivot” or the “Company”), is pleased to announce that it has filed three...
Pivot Pharmaceuticals To Commence Trading on CSE
December 18, 2017 05:00 ET
|
Pivot Pharmaceuticals Inc.
VANCOUVER, British Columbia, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Pivot Pharmaceuticals Inc. (OTCQB:PVOTF) (“Pivot” or the “Company”), an emerging biopharmaceutical company, is pleased to announce that...